MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$4.10
-0.06 (-1.44%)
Financial Highlights (FY 2026)
Revenue
431.40M
Net Income
50.05M
Gross Margin
82.6%
Profit Margin
11.6%
Rev Growth
+16.1%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 431.40M | 371.71M | 190.63M | 232.96M |
| Gross Profit | 356.17M | 306.88M | 62.11M | 75.91M |
| Operating Income | 65.83M | 51.05M | 26.66M | 33.71M |
| Net Income | 50.05M | 38.81M | 27.70M | 27.53M |
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
| Rev Growth | +16.1% | +16.1% | +8.9% | +19.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 20.69M | 20.69M | 233.39M | 246.36M |
| Total Equity | 295.61M | 295.61M | 355.89M | 342.73M |
| D/E Ratio | 0.07 | 0.07 | 0.66 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 67.29M | 55.08M | 34.17M | 44.70M |
| Free Cash Flow | — | — | 29.04M | 38.48M |